Tuesday, February 08, 2022 9:08:51 AM
9:01 AM ET 2/8/22 | Dow Jones
CALGARY, AB / ACCESSWIRE / February 8, 2022 / CannaPharmaRx, Inc. (OTC PINK:CPMD), a future leader in ultramodern, highly efficient cannabis production facilities in Canada, announced today that it will no longer will be issuing shares under the previously effective S-1.
The S-1 included 135,000,000 registered shares and was filed on May 15, 2021. The S-1 went effective on June 11, 2021.
"While some shares have been issued and converted previously under the S-1 to advance the company to the stage it is currently at, it no longer makes sense to utilize the shares still available. We have received alternative funding, leased new facilities, and will be able to generate significant cash flow moving forward. We believe this is an important step for investors, as it limits any further dilution from these shares, " stated Nick Colvin, CEO of CannapharmaRx.
About CannapharmaRx, Inc.
CannapharmaRx is focused on the acquisition and development of state-of-the-art cannabis grow facilities in Canada. CPMD is in discussion with other companies regarding potential acquisitions. CannapharmaRx's business strategy is to become a leader in high quality and low-cost production of cannabis through the development, acquisition, and enhancement of existing facilities. CannapharmaRx is committed to operating high-quality facilities utilizing the latest technology in combined heat and power generation to ensure being a low-cost producer of cannabis.
Safe Harbor Statement
Cautionary Note Regarding Forward-Looking Information or Statements
This press release contains forward-looking information or statements. All statements that are or information which is not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance, are 'forward-looking information or statements.' Forward-looking information or statements can be identified by the use of words such as 'plans,' 'expects,' or 'does not expect,' 'is expected,' 'estimates,' 'intends,' 'anticipates,' or 'does not anticipate,' or 'believes,' or variations of such words and phrases or statements that certain actions, events or results 'may,' 'could,' 'would,' 'might' or 'will' be taken, occur or be achieved. With respect to forward-looking information and statements contained herein, Management of CannapharmaRx has made numerous assumptions, including, among other things, assumptions about general business and economic conditions. Such forward-looking statements are based on assumptions and involve known and unknown risks, uncertainties, and other factors that may cause actual results, events, or developments to be materially different from any future results, events, or developments expressed or implied by such forward-looking information or statements. Readers are cautioned not to place undue reliance on such forward-looking information or statements. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking information or statements. CannapharmaRx assumes no obligation to update any forward-looking information or statements, even if new information becomes available as a result of future events, new information, or for any other reason except as required by law.
Contact Information:
Brokers and Analysts:
Chesapeake Group
(410) 825-3930
SOURCE: CannaPharmaRx, Inc.
View source version on accesswire.com:
https://www.accesswire.com/687683/CannaPharmaRx-Stops-Issuing-Shares-Under-Previously-Effective-S-1
> Dow Jones Newswires
February 08, 2022 09:01 ET (14:01 GMT)
May the Market Makers forever look favorably upon you.
Recent CPMD News
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 02/22/2024 12:55:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 05:02:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 09:01:08 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:05:45 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 08:01:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 06:51:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/13/2023 06:38:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/13/2023 02:20:32 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 06:13:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/22/2023 06:51:11 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/01/2023 05:08:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2023 08:21:42 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM